Literature DB >> 28166637

Computational Multitarget Drug Design.

Weilin Zhang1, Jianfeng Pei2, Luhua Lai1,2,3.   

Abstract

Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases. Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration. Many in silico methods have been developed to approach different aspects of this polypharmacology-guided drug design, particularly for drug repurposing and multitarget drug design. In this review, we summarize recent progress in computational multitarget drug design and discuss their advantages and limitations. Perspectives for future drug development will also be discussed.

Mesh:

Substances:

Year:  2017        PMID: 28166637     DOI: 10.1021/acs.jcim.6b00491

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  29 in total

1.  Multiple Target Drug Design Using LigBuilder 3.

Authors:  Xiaoyu Qing; Shiwei Wang; Yaxia Yuan; Jianfeng Pei; Luhua Lai
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Recent progress on cheminformatics approaches to epigenetic drug discovery.

Authors:  Zoe Sessions; Norberto Sánchez-Cruz; Fernando D Prieto-Martínez; Vinicius M Alves; Hudson P Santos; Eugene Muratov; Alexander Tropsha; José L Medina-Franco
Journal:  Drug Discov Today       Date:  2020-09-30       Impact factor: 7.851

Review 3.  Translating Knowledge Into Therapy for Acute Kidney Injury.

Authors:  Mark de Caestecker; Raymond Harris
Journal:  Semin Nephrol       Date:  2018-01       Impact factor: 5.299

4.  Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer.

Authors:  Anshika N Singh; Neeti Sharma
Journal:  Protein J       Date:  2019-10       Impact factor: 2.371

5.  Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.

Authors:  Shayma El-Atawneh; Amiram Goldblum
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

6.  Potential Multifunctional Bioactive Compounds from Dysosma versipellis Explored by Bioaffinity Ultrafiltration-HPLC/MS with Topo I, Topo II, COX-2 and ACE2.

Authors:  Huixia Feng; Guilin Chen; Yongli Zhang; Mingquan Guo
Journal:  J Inflamm Res       Date:  2022-08-15

7.  A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.

Authors:  Bashir Lawal; Wen-Cheng Lo; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander Th Wu; Hsu-Shan Huang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Introducing the metacore concept for multi-target ligand design.

Authors:  Dagmar Stumpfe; Alexander Hoch; Jürgen Bajorath
Journal:  RSC Med Chem       Date:  2021-04-15

9.  Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays.

Authors:  Christian Feldmann; Dimitar Yonchev; Jürgen Bajorath
Journal:  Future Sci OA       Date:  2021-03-11

10.  Compound dataset and custom code for deep generative multi-target compound design.

Authors:  Thomas Blaschke; Jürgen Bajorath
Journal:  Future Sci OA       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.